Usefulness of 18F-fluorodeoxyglucose positron emission tomography in differential diagnosis and staging of cholangiocarcinomas

Journal of Gastroenterology and Hepatology (Australia)

Volumn 23, Issue 5, 2008, Pages 759-765

  Moon, Chang Mo ^a   Bang, Seungmin ^a   Chung, Jae Bock ^a   Park, Seung Woo ^a   Song, Si Young ^a   Yun, Mijin ^a   Lee, Jong Doo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Cholangiocarcinoma; Computed tomography; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BILE DUCT CANCER; BILE DUCT CARCINOMA; BILE DUCT TUMOR; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAHEPATIC BILE DUCT; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SCINTISCANNING;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES;

EID: 42049101480     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2007.05173.x     Document Type: Article

References (40)

1. Khan SA, Davidson BR, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002 51 (Suppl. 6 VI1 9.
2. de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM. Biliary tract cancers. N. Engl. J. Med. 1999 341 : 1368 79.
3. Gores GJ. Early detection and treatment of cholangiocarcinoma. Liver Transpl. 2000 6 (Suppl. 2 S30 4.
4. Filer JS, Muecker MM, Usher P, Lodish HF. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 1987 235 : 1492 5.
5. 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000 20 : 109 16.
6. Schiepers C, Penninckx F, deVadder N. Contribution of PET in the diagnosis of recurrent colorectal cancer: comparison with conventional imaging. Eur. J. Surg. Oncol. 1995 21 : 517 22.
7. Lowe VJ, Fletcher JW, Gobar L. Prospective investigation of positron emission tomography in lung nodules. J. Clin. Oncol. 1998 16 : 1075 84.
8. Shiomi S, Nishiguchi S, Ishizu H et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am. J. Gastroenterol. 2001 96 : 1877 80.
9. Higashi T, Tamaki N, Honda T et al. Expression of glucose transporters in human pancreatic tumours compared with increased FDG accumulation in PET study. J. Nucl. Med. 1997 38 : 1337 44.
10. Scheck N, Hall BL, Finn OJ. Increased glyceraldehydes-3-phosphate dehydrogenase gene expression in human pancreatic adenocarcinoma. Cancer Res. 1988 48 : 6354 9.
11. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cells? In vivo comparison with DNA flow cytometry and tritiated thymidine uptake. J. Nucl. Med. 1993 34 : 414 19.
12. 18F]fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer. Hepatology 2001 33 : 1029 35.
13. Keiding S, Hansen SB, Rasmussen HH et al. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography. Hepatology 1998 28 : 700 6.
14. Delbeke D, Martin WH, Sandler MP et al. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch. Surg. 1998 133 : 510 15.
15. 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur. J. Nucl. Med. Mol. Imaging 2003 30 : 1467 72.
16. Kato T, Tsukamoto E, Kuge Y et al. Clinical role of [18]F-FDG PET for initial staging of patients with extrahepatic bile duct cancer. Eur. J. Nucl. Med. 2002 29 : 1047 54.
17. Fritscher-Ravens A, Bohuslavizki KH, Broering DC et al. FDG PET in the diagnosis of hilar cholangiocarcinoma. Nucl. Med. Commun. 2001 22 : 1277 85.
18. Anderson CD, Rice MH, Pinson CW et al. Fluorodeoxyglucose PET imaging in the evaluation of Gallbladder Carcinoma and Cholangiocarcinoma. J. Gastrointest. Surg. 2004 8 : 90 7.
19. Domagk D, Wessling J, Reimer P et al. Endoscopic retrograde cholangiopancreatography, intraductal ultrasonography, and magnetic resonance cholangiopancreatography in bile duct strictures: a prospective comparison of imaging diagnostics with histopathological correlation. Am. J. Gastroenterol. 2004 99 : 1684 9.
20. Romagnuolo J, Bardou M, Rahme E et al. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann. Intern. Med. 2003 139 : 547 57.
21. Fritscher-Ravens A, Broering DC, Knoefel WT et al. EUS-guided fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially operable patients with negative brush cytology. Am. J. Gastroenterol. 2004 99 : 45 51.
22. Pugliese V, Conio M, Nicolo G et al. Endoscopic retrograde forceps biopsy and brush cytology of biliary strictures: a prospective study. Gastrointest. Endosc. 1995 42 : 520 6.
23. Schoefl R, Haefner M, Wrba F et al. Forceps biopsy and brush cytology during endoscopic retrograde cholangiopancreatography for the diagnosis of biliary stenoses. Scand. J. Gastoenterol. 1997 32 : 363 8.
24. Glasbrenner B, Ardan M, Boeck W et al. Prospective evaluation of brush cytology strictures during endoscopic retrograde cholangiopancreatography. Endoscopy 1999 31 : 712 17.
25. Delbeke D, Rose DM, Chapman WC et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J. Nucl. Med. 1999 40 : 1784 91.
26. Vansteenkiste JF, Stroobants SG, Dupont PJ et al. Prognostic importance of the standardized uptake value on (18) F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J. Clin. Oncol. 1999 17 : 3201 6.
27. 18FDG uptake in soft tissue masses. Eur. J. Nucl. Med. 1999 26 : 22 30.
28. Folpe AL, Lyles RH, Sprouse JT et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin. Cancer Res. 2000 6 : 1279 87.
29. 18F-fluorodeoxyglucose positron emission tomography. Am. J. Roentgenol. 1997 168 : 417 24.
30. Meltzer CC, Luketich JD, Friedman D et al. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer: comparison with computed tomography. Clin. Nucl. Med. 2000 25 : 882 7.
31. 18F-FDG positron emission tomography in gastric and oesophageal carcinoma. Br. J. Radiol. 1999 72 : 525 9.
32. Kalady MF, Clary BM, Clark LA et al. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann. Surg. Oncol. 2002 9 : 237 42.
33. 18F- fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic cancer. Gastroenterol. Clin. Biol. 2002 9 : 799 806.
34. Bares R, Dohmen BM, Cremerius U et al. Results of positron emission tomography with fluorine-18 labelled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma. Radiologe 1996 36 : 435 40.
35. Abdel-Nabi H, Doerr RJ, Lamonica DM et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998 206 : 755 60.
36. Lardinois D, Weder W, Hany TF et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N. Engl. J. Med. 2003 348 : 2500 7.
37. Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann. Surg. 2004 240 : 1027 34.
38. Heinrich S, Goerres GW, Schafer M et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann. Surg. 2005 242 : 235 43.
39. Reinhardt MJ, Strunk H, Gerhardt T et al. Detection of Klatskin's tumor in extrahepatic bile duct strictures using delayed 18F-FDG PET/CT: preliminary results for 22 patient studies. J. Nucl. Med. 2005 46 : 1158 63.
40. Petrowsky H, Wildbrett P, Husarik DB et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J. Hepatol. 2006 45 : 43 50.